Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Dec 06 04:00PM ET
3.10
Dollar change
+0.06
Percentage change
1.97
%
Index- P/E5.71 EPS (ttm)0.54 Insider Own58.26% Shs Outstand224.34M Perf Week8.01%
Market Cap709.07M Forward P/E- EPS next Y-0.54 Insider Trans0.00% Shs Float93.63M Perf Month8.39%
Income123.50M PEG- EPS next Q-0.22 Inst Own5.18% Short Float4.71% Perf Quarter6.16%
Sales595.81M P/S1.19 EPS this Y167.27% Inst Trans-6.56% Short Ratio9.20 Perf Half Y-30.96%
Book/sh3.61 P/B0.86 EPS next Y-164.63% ROA13.38% Short Interest4.41M Perf Year-43.33%
Cash/sh2.69 P/C1.15 EPS next 5Y-10.76% ROE17.08% 52W Range2.21 - 6.30 Perf YTD-26.37%
Dividend Est.- P/FCF6.26 EPS past 5Y-23.15% ROI14.57% 52W High-50.79% Beta2.59
Dividend TTM- Quick Ratio6.19 Sales past 5Y54.58% Gross Margin67.78% 52W Low39.95% ATR (14)0.17
Dividend Ex-Date- Current Ratio6.20 EPS Y/Y TTM135.95% Oper. Margin30.20% RSI (14)65.33 Volatility6.36% 6.26%
Employees1172 Debt/Eq0.06 Sales Y/Y TTM1202.27% Profit Margin20.73% Recom2.17 Target Price6.80
Option/ShortYes / Yes LT Debt/Eq0.05 EPS Q/Q797.21% Payout- Rel Volume1.67 Prev Close3.04
Sales Surprise14253.43% EPS Surprise3.85% Sales Q/Q2925.93% EarningsNov 12 BMO Avg Volume479.64K Price3.10
SMA2012.10% SMA5010.01% SMA200-2.12% Trades Volume801,433 Change1.97%
Date Action Analyst Rating Change Price Target Change
Apr-25-24Downgrade Leerink Partners Outperform → Market Perform $12 → $4
Jun-08-23Initiated SVB Securities Outperform $13
Jan-19-23Upgrade UBS Neutral → Buy $8 → $18
Jan-09-23Upgrade Jefferies Hold → Buy $9 → $21
Jan-21-22Downgrade BofA Securities Neutral → Underperform $55 → $20
Jan-18-22Initiated JMP Securities Mkt Outperform $52
Oct-22-21Initiated Deutsche Bank Hold $35
Jun-17-21Downgrade BofA Securities Buy → Neutral $50
Apr-26-21Resumed Credit Suisse Underperform
Apr-26-21Initiated Guggenheim Neutral
Nov-20-24 11:18AM
Nov-19-24 06:31PM
Nov-15-24 02:08AM
Nov-13-24 02:13AM
Nov-12-24 07:20AM
07:30AM Loading…
Nov-07-24 07:30AM
Nov-04-24 07:20AM
07:15AM
Oct-30-24 07:34AM
Oct-28-24 08:10AM
Oct-22-24 06:24PM
Oct-08-24 05:50AM
Sep-13-24 08:15AM
Sep-12-24 07:15AM
Sep-09-24 07:15AM
07:07PM Loading…
Aug-16-24 07:07PM
Aug-15-24 07:30AM
07:20AM
07:15AM
Aug-08-24 10:00AM
Jul-15-24 12:00PM
Jul-12-24 10:53AM
Jul-11-24 07:15AM
07:00AM
Jul-04-24 09:58PM
06:33AM
Jul-03-24 12:49PM
12:41PM
11:49AM
11:12AM
10:51AM Loading…
10:51AM
10:18AM
10:09AM
08:19AM
07:43AM
07:21AM
06:23AM
06:12AM
04:43AM
02:40AM
02:40AM
02:25AM
Jun-24-24 04:20PM
Jun-18-24 06:59PM
Jun-03-24 06:48PM
May-28-24 07:20AM
May-23-24 07:58PM
12:45PM
07:20AM
May-15-24 01:54PM
May-10-24 06:36AM
Apr-25-24 01:30PM
05:10AM
Apr-24-24 12:27PM
07:30AM
07:20AM
07:20AM
06:22AM
Apr-18-24 07:15AM
Apr-16-24 07:15AM
Apr-04-24 09:10AM
07:15AM
Feb-22-24 06:55PM
Jan-26-24 09:35AM
Jan-25-24 09:35AM
Jan-05-24 10:47AM
07:30AM
Dec-30-23 08:49AM
Dec-19-23 10:15PM
01:43PM
12:31PM
09:35AM
09:12AM
08:35AM
Nov-21-23 09:55AM
Nov-20-23 03:41PM
Nov-15-23 01:58PM
02:03AM
Nov-14-23 07:30AM
Nov-01-23 08:15AM
Oct-31-23 07:12PM
Sep-29-23 09:07AM
Sep-28-23 11:27AM
07:15AM
04:16AM
Sep-27-23 06:44PM
Sep-12-23 07:15AM
Aug-17-23 07:15AM
Aug-08-23 06:26AM
Aug-01-23 07:15AM
Jul-20-23 06:01AM
Jul-14-23 07:15AM
Jul-13-23 07:15AM
Jun-28-23 02:40PM
Jun-23-23 12:35PM
Jun-20-23 06:29PM
07:25AM
07:10AM
Jun-19-23 01:33PM
Jun-01-23 02:15PM
CureVac BV is a clinical-stage biopharmaceutical company, which engages in developing transformative medicines based on messenger ribonucleic acid (mRNA). Its product portfolio includes clinical and preclinical candidates across multiple disease indications in prophylactic vaccines, oncology, and protein therapy. The company was founded by Ingmar Hoerr and Florian von der Mulbe in 2000 and is headquartered in Tubingen, Germany.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Pierre KemulaaffiliateSep 27 '24Proposed Sale3.0855169Sep 27 12:48 PM
Pierre KemulaaffiliateSep 25 '24Proposed Sale3.1034,000105,400Sep 25 02:19 PM